TherapeuticsMD (NASDAQ:TXMD) Downgraded to Neutral at HC Wainwright

TherapeuticsMD (NASDAQ:TXMD – Get Rating) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report released on Tuesday, The Fly reports.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, May 26th. Cantor Fitzgerald cut shares of TherapeuticsMD from an “overweight” rating to a “neutral” rating in a report on Friday, May 6th.

Shares of TXMD traded down $0.04 during mid-day trading on Tuesday, hitting $9.93. 713,873 shares of the company’s stock were exchanged, compared to its average volume of 594,288. The stock’s 50-day moving average is $9.77 and its 200-day moving average is $15.07. TherapeuticsMD has a fifty-two week low of $1.99 and a fifty-two week high of $69.50. The company has a market cap of $86.08 million, a price-to-earnings ratio of -0.46 and a beta of 2.10.

TherapeuticsMD (NASDAQ:TXMD – Get Rating) last issued its quarterly earnings results on Monday, May 16th. The company reported ($5.69) EPS for the quarter, missing the consensus estimate of ($3.50) by ($2.19). During the same quarter in the prior year, the firm earned ($5.50) EPS. As a group, research analysts predict that TherapeuticsMD will post -7.51 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TXMD. Spire Wealth Management purchased a new stake in TherapeuticsMD during the fourth quarter worth approximately $25,000. Point72 Hong Kong Ltd acquired a new position in shares of TherapeuticsMD in the 3rd quarter valued at $27,000. Janus Henderson Group PLC purchased a new position in shares of TherapeuticsMD in the 3rd quarter valued at $28,000. Centiva Capital LP purchased a new position in shares of TherapeuticsMD in the 3rd quarter valued at $30,000. Finally, Macquarie Group Ltd. acquired a new stake in TherapeuticsMD during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 33.91% of the company’s stock.

TherapeuticsMD Company Profile (Get Rating)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Further Reading

• Get a free copy of the StockNews.com research report on TherapeuticsMD (TXMD)
• It’s Time To PLAY With Dave & Buster’s
• Seagate Technology: Improved Fundamentals & Recovering Technicals
• It’s A Sweet Time To Buy The J.M. Smucker Co. 
• Don’t Rush Out To Buy G-III Apparel 
• Target’s Warning Is Dire News For The S&P 500 

Want More Great Investing Ideas?